ArticleCancer chemotherapy and pharmacology2018

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

Emma Dean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.